- Trials with a EudraCT protocol (288)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
288 result(s) found for: SARS coronavirus.
Displaying page 6 of 15.
EudraCT Number: 2020-002542-16 | Sponsor Protocol Number: INSIGHT013 | Start Date*: 2020-09-30 | |||||||||||
Sponsor Name:Office of Sponsored Projects, Regents of the University of Minnesota | |||||||||||||
Full Title: An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the... | |||||||||||||
Medical condition: COVID-19 (SARS-CoV-2) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) DK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001793-30 | Sponsor Protocol Number: 20200412 | Start Date*: 2020-07-01 | |||||||||||||||||||||
Sponsor Name:Copenhagen University Hospital of Bispebjerg | |||||||||||||||||||||||
Full Title: Preventing Disease Aggravation in COVID-19 by high dose Vitamin D: a randomized trial (COVIT-D) | |||||||||||||||||||||||
Medical condition: SARS-COV-2 positive patients | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001770-30 | Sponsor Protocol Number: 2020COVID-19TCZ | Start Date*: 2020-04-21 | |||||||||||
Sponsor Name:CHU AMBROISE PARE | |||||||||||||
Full Title: COVID 19: Experimental use of tocilizumab (Roactemra®) in severe SARS-CoV-2 related pneumonia. | |||||||||||||
Medical condition: viral pneumonia caused by the new coronavirus (SARS-CoV-2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006960-26 | Sponsor Protocol Number: NOR-LAABis-2022 | Start Date*: 2022-11-04 | ||||||||||||||||
Sponsor Name:Oslo University Hospital - Rikshospitalet | ||||||||||||||||||
Full Title: COVID-19 PROPHYLAXIS IN IMMUNOSUPPRESSED PATIENTS WITH NO/POOR SARS-COV-2 VACCINE RESPONSE USING LONG-ACTING ANTIBODIES (AZD7442) | ||||||||||||||||||
Medical condition: Kidney transplant recipients with suboptimal immune response to previous SARS-CoV-2 vaccinations | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NO (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001852-16 | Sponsor Protocol Number: 01-04-2020 | Start Date*: 2020-07-14 | |||||||||||
Sponsor Name:Maxima MC | |||||||||||||
Full Title: Effect of Iodine treatment in patiënts with COVID-19 disease | |||||||||||||
Medical condition: SARS-CoV-2 infection causing COVID-19 disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001632-10 | Sponsor Protocol Number: SARS-CoV-2CP-HD-001 | Start Date*: 2020-05-04 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Ruprecht-Karls-Universität Heidelberg, Medical Faculty, University Hospital Heidelberg - | ||||||||||||||||||||||||||||||||||||||
Full Title: A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 D... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) / SARS-CoV-2 Disease | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004571-41 | Sponsor Protocol Number: RBMinCovid19 | Start Date*: 2021-02-23 | |||||||||||
Sponsor Name:Cyxone AB | |||||||||||||
Full Title: A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19) | |||||||||||||
Medical condition: Coronavirus Disease (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Prematurely Ended) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001769-19 | Sponsor Protocol Number: CVG01 | Start Date*: 2021-04-15 | |||||||||||
Sponsor Name:GUVAX (Gothenburg University Vaccine Research Institute) | |||||||||||||
Full Title: Immune response to SARS-CoV-2 in health care workers, previously infected subjects, and immunocompromised subjects, before and after Covid-19 vaccination: a phase IV trial | |||||||||||||
Medical condition: SARS-COV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000843-33 | Sponsor Protocol Number: FERMIN | Start Date*: 2021-04-23 | |||||||||||||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||||||||||||
Full Title: Fenofibrate as a Metabolic Intervention for Coronavirus Disease 2019 (COVID-19): A randomized controlled trial (FERMIN trial) | |||||||||||||||||||||||
Medical condition: Coronavirus disease-19 | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GR (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000307-20 | Sponsor Protocol Number: COMB157GDE01 | Start Date*: 2021-04-28 | |||||||||||
Sponsor Name:Novartis Pharma Vertriebs GmbH | |||||||||||||
Full Title: Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS) | |||||||||||||
Medical condition: relapsing multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003369-20 | Sponsor Protocol Number: CT-P59_3.2 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute R... | |||||||||||||
Medical condition: SARS CoV 2 infection in outpatients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) RO (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001224-33 | Sponsor Protocol Number: COV-HCQ | Start Date*: 2020-03-25 | |||||||||||
Sponsor Name:Universitätsklinikum Tübingen | |||||||||||||
Full Title: Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19 | |||||||||||||
Medical condition: Acute coronavirus disease 2019 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004272-17 | Sponsor Protocol Number: CLO-SCB-2019-003 | Start Date*: 2021-03-25 | |||||||||||
Sponsor Name:Clover Biopharmaceuticals AUS Pty Ltd | |||||||||||||
Full Title: A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (S... | |||||||||||||
Medical condition: SARS-CoV-2-mediated COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000509-26 | Sponsor Protocol Number: ANRS0002S | Start Date*: 2021-02-24 | |||||||||||
Sponsor Name:Inserm-ANRS | |||||||||||||
Full Title: A phase II trial assessing immunogenicity and safety of COVID-19 mRNA Vaccine BNT162b2 in adult volunteers with no history of SARS CoV-2 infection administered with two doses of vaccine (D1-D29) an... | |||||||||||||
Medical condition: Healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001708-41 | Sponsor Protocol Number: X-COVID19 | Start Date*: 2020-04-24 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA | |||||||||||||
Full Title: Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. versus 40 mg b.i.d. A randomized Clinical Trial | |||||||||||||
Medical condition: SARS-CoV-2 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001467-82 | Sponsor Protocol Number: P020.051 | Start Date*: 2020-10-23 | ||||||||||||||||
Sponsor Name:Leiden University Medical Center | ||||||||||||||||||
Full Title: An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients – the VOCOVID Study (COVID-19) | ||||||||||||||||||
Medical condition: SARS-CoV-2 infection in Kidney Transplant Recipients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001558-23 | Sponsor Protocol Number: COFID19-AIFA17/2020 | Start Date*: 2020-04-09 | |||||||||||
Sponsor Name:ASUR (Azienda Sanitaria Unica Regionale) Marche | |||||||||||||
Full Title: Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients. Hydro-Stop-COVID19 Trial | |||||||||||||
Medical condition: Emerging disease (COVID-19) due to a novel coronavirus (named SARS-CoV-2 latter) started in Wuhan, China and rapidly spread in China and outside and has been declared pandemic by WHO on March 12th ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000269-34 | Sponsor Protocol Number: GC2010 | Start Date*: 2021-03-20 | ||||||||||||||||||||||||||
Sponsor Name:Grifols Therapeutics LLC | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) versus Placebo in Asymptomatic Ambulatory... | ||||||||||||||||||||||||||||
Medical condition: Subjects with laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by qualitative PCR (reverse transcriptase [RT]-PCR) that are asymptomathic | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-002274-28 | Sponsor Protocol Number: COVID-VIT-D | Start Date*: 2020-05-19 | |||||||||||
Sponsor Name:Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturias (FINBA) | |||||||||||||
Full Title: Usefulness of vitamin D on morbidity and mortality of SARS-COV-2 virus infection (Covid-19) at the Central University Hospital of Asturias | |||||||||||||
Medical condition: SARS-COV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000623-13 | Sponsor Protocol Number: VIR-7831-5008 | Start Date*: 2021-07-29 | ||||||||||||||||
Sponsor Name:Vir Biotechnology, Inc. | ||||||||||||||||||
Full Title: A Phase 3 randomized, multi-center, open label study to assess the efficacy, safety, and tolerability of monoclonal antibody VIR-7831 (sotrovimab) given intramuscularly versus intravenously for the... | ||||||||||||||||||
Medical condition: Mild/moderate COVID-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) AT (Completed) IT (Ongoing) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
